These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32715623)

  • 1. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
    Boada M; López OL; Olazarán J; Núñez L; Pfeffer M; Paricio M; Lorites J; Piñol-Ripoll G; Gámez JE; Anaya F; Kiprov D; Lima J; Grifols C; Torres M; Costa M; Bozzo J; Szczepiorkowski ZM; Hendrix S; Páez A
    Alzheimers Dement; 2020 Oct; 16(10):1412-1425. PubMed ID: 32715623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroimaging analyses from a randomized, controlled study to evaluate plasma exchange with albumin replacement in mild-to-moderate Alzheimer's disease: additional results from the AMBAR study.
    Cuberas-Borrós G; Roca I; Castell-Conesa J; Núñez L; Boada M; López OL; Grifols C; Barceló M; Pareto D; Páez A
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4589-4600. PubMed ID: 35867135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
    Boada M; López OL; Olazarán J; Núñez L; Pfeffer M; Puente O; Piñol-Ripoll G; Gámez JE; Anaya F; Kiprov D; Alegret M; Grifols C; Barceló M; Bozzo J; Szczepiorkowski ZM; Páez A;
    Alzheimers Dement; 2022 Jul; 18(7):1314-1324. PubMed ID: 34726348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility, safety, and tolerability of two modalities of plasma exchange with albumin replacement to treat elderly patients with Alzheimer's disease in the AMBAR study.
    Boada M; Kiprov D; Anaya F; López OL; Núñez L; Olazarán J; Lima J; Grifols C; Barceló M; Rohe R; Prieto-Fernández C; Szczepiorkowski ZM; Páez A
    J Clin Apher; 2023 Feb; 38(1):45-54. PubMed ID: 36305459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Alzheimer disease using combination therapy with plasma exchange and haemapheresis with albumin and intravenous immunoglobulin: Rationale and treatment approach of the AMBAR (Alzheimer Management By Albumin Replacement) study.
    Boada M; Ramos-Fernández E; Guivernau B; Muñoz FJ; Costa M; Ortiz AM; Jorquera JI; Núñez L; Torres M; Páez A
    Neurologia; 2016 Sep; 31(7):473-81. PubMed ID: 25023458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet.
    Monteiro C; Toth B; Brunstein F; Bobbala A; Datta S; Ceniceros R; Sanabria Bohorquez SM; Anania VG; Wildsmith KR; Schauer SP; Lee J; Dolton MJ; Ramakrishnan V; Abramzon D; Teng E;
    Neurology; 2023 Oct; 101(14):e1391-e1401. PubMed ID: 37643887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma exchange for Alzheimer's disease Management by Albumin Replacement (AMBAR) trial: Study design and progress.
    Boada M; López O; Núñez L; Szczepiorkowski ZM; Torres M; Grifols C; Páez A
    Alzheimers Dement (N Y); 2019; 5():61-69. PubMed ID: 30859122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial.
    Boada M; Anaya F; Ortiz P; Olazarán J; Shua-Haim JR; Obisesan TO; Hernández I; Muñoz J; Buendia M; Alegret M; Lafuente A; Tárraga L; Núñez L; Torres M; Grifols JR; Ferrer I; Lopez OL; Páez A
    J Alzheimers Dis; 2017; 56(1):129-143. PubMed ID: 27911295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMBAR, an Encouraging Alzheimer's Trial That Raises Questions.
    Loeffler DA
    Front Neurol; 2020; 11():459. PubMed ID: 32547478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intensive lifestyle changes on the progression of mild cognitive impairment or early dementia due to Alzheimer's disease: a randomized, controlled clinical trial.
    Ornish D; Madison C; Kivipelto M; Kemp C; McCulloch CE; Galasko D; Artz J; Rentz D; Lin J; Norman K; Ornish A; Tranter S; DeLamarter N; Wingers N; Richling C; Kaddurah-Daouk R; Knight R; McDonald D; Patel L; Verdin E; E Tanzi R; Arnold SE
    Alzheimers Res Ther; 2024 Jun; 16(1):122. PubMed ID: 38849944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Neuroimaging Analysis in Mild-Moderate Alzheimer's Disease Patients Treated with Plasma Exchange with 5% Human Albumin.
    Cuberas-Borrós G; Roca I; Boada M; Tárraga L; Hernández I; Buendia M; Rubio L; Torres G; Bittini Á; Guzmán-de-Villoria JA; Pujadas F; Torres M; Núñez L; Castell J; Páez A
    J Alzheimers Dis; 2018; 61(1):321-332. PubMed ID: 29154283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of therapeutic and low volume plasma exchange on clinical laboratory parameters in patients treated for Alzheimer's disease from the AMBAR study.
    Grifols C; Barceló M; Núñez L; Szczepiorkowski ZM; Boada M; López OL; Páez A
    Ther Apher Dial; 2023 Oct; 27(5):949-959. PubMed ID: 37211527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal clinically important difference in Alzheimer's disease: Rapid review.
    Muir RT; Hill MD; Black SE; Smith EE
    Alzheimers Dement; 2024 May; 20(5):3352-3363. PubMed ID: 38561021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic plasma exchange with albumin: a new approach to treat Alzheimer's disease.
    Boada M; Martínez-Lage P; Serrano-Castro P; Costa M; Páez A
    Expert Rev Neurother; 2021 Aug; 21(8):843-849. PubMed ID: 34338566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of anti-Aβ agents for delaying cognitive decline in Alzheimer's disease: a meta-analysis.
    Li J; Wu X; Tan X; Wang S; Qu R; Wu X; Chen Z; Wang Z; Chen G
    Front Aging Neurosci; 2023; 15():1257973. PubMed ID: 38020763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
    Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.